The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aclaris Therapeutics, Inc. COM 00461U105   13,047,980 1,258,243 SH   SOLE   1,258,243 0 0
Compass Therapeutics, Inc. COM 20454B104   4,210,546 1,324,071 SH   SOLE   1,324,071 0 0
Disc Medicine, Inc. COM 254604101   10,811,977 243,513 SH   SOLE   243,513 0 0
Hims & Hers Health, Inc. COM CL A 433000106   35,093,781 3,733,381 SH   SOLE   3,733,381 0 0
Kinnate Biopharma Inc. COM 49705R105   10,683,650 3,525,957 SH   SOLE   3,525,957 0 0
Pardes Biosciences Inc COM 69945Q105   19,569,515 10,811,887 SH   SOLE   10,811,887 0 0
Pharvaris N.V. COM N69605108   516,910 34,142 SH   SOLE   34,142 0 0
Quantum Si Inc COM CL A 74765K105   1,654,683 924,404 SH   SOLE   924,404 0 0
Somalogic, Inc. COM CL A 83444K105   7,861,568 3,403,276 SH   SOLE   3,403,276 0 0
Theseus Pharmaceuticals, Inc. COM 88369M101   33,451,278 3,585,346 SH   SOLE   3,585,346 0 0